A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Part of paid clinical trials in Paradise Valley, Arizona.
- Sponsor
- Genentech, Inc.
- Study ID
- NCT00381810
- Phase
- PHASE3
- Status
- Terminated
Conditions
- Lupus Erythematosus, Systemic
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUGRituximab will be supplied as a liquid for intravenous infusion.
- Methylprednisolone — DRUG
- Acetaminophen — DRUG
- Diphenhydramine — DRUG
Study Details
This is a Phase II/III open label, single-arm, multicenter, extension study to evaluate the safety and efficacy of rituximab when administered on a scheduled basis every 6 months over the course of 1 year with reassessment of response at 12 months. This study is open to participants previously enrolled in Genentech Study U2971g only.
Key Dates
- Start date
- Jun 22, 2006
- Status verified
- Jun 2017
- Primary completion
- Jul 31, 2008
- Completion
- Feb 29, 2012
Study Design
- Enrollment
- 31 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Rituximab 1000 mgParticipants will receive rituximab 1000 mg intravenously twice, 14 days apart at study entry and again 6 months later. Participants will also receive methylprednisolone 100 or 125 mg IV, acetaminophen 1000 mg orally, and diphenhydramine 50 mg orally prior to study drug infusion.
Primary Outcome Measure
Percentage of Participants With at Least 1 Serious Adverse Event [ Time Frame: Baseline to the end of the study (up to 52 weeks) ]
Locations (11)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Arizona Arthritis & Rheumatology Research, Pllc | Paradise Valley | Arizona | 85253 | - |
| Eden Medical Center San Leandro Hospital | San Leandro | California | 94578 | - |
| Intermountain Research Center | Boise | Idaho | 83702 | - |
| Coeur D'Alene Arthritis Clinic | Coeur d'Alene | Idaho | 83814 | - |
| University of Chicago | Chicago | Illinois | 60637 | - |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | - |
| North Shore - Long Island Jewish Hospital Health System; Rheumatology & Allergy- Clinical Immunology | Great Neck | New York | 11021 | - |
| Oklahoma Medical Research Foundation | Oklahoma City | Oklahoma | 73104 | - |
| Medical Univ of South Carolina | Charleston | South Carolina | 29425 | - |
| Texas Research Center | Sugar Land | Texas | 77479 | - |
| Seattle Rheumatology Assoc; Swedish Rheumatology Research | Seattle | Washington | 98104 | - |
Find similar trials in Paradise Valley, AZ
By research site
Arizona Arthritis & Rheumatology Research, Pllc· Paradise Valley, AZEden Medical Center San Leandro Hospital· San Leandro, CAIntermountain Research Center· Boise, IDCoeur D'Alene Arthritis Clinic· Coeur d'Alene, IDUniversity of Chicago· Chicago, ILUniversity of Kansas Medical Center· Kansas City, KS
Related Studies
- Trial of Belimumab in Early LupusPHASE4 · Recruiting · Northwell Health · Manhasset, New York
- Engagement in CHildhood-Onset Systemic LupusEnrolling By Invitation · Montefiore Medical Center · The Bronx, New York
- Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus ErythematosusPHASE3 · Enrolling By Invitation · Viatris Innovation GmbH · Clearwater, Florida
- A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)PHASE2 · Recruiting · Novartis Pharmaceuticals · Birmingham, Alabama